Cargando…

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS prenyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Odeniyide, Patience, Yohe, Marielle E., Pollard, Kai, Vaseva, Angelina V., Calizo, Ana, Zhang, Lindy, Rodriguez, Fausto J., Gross, John M., Allen, Amy N., Wan, Xiaolin, Somwar, Romel, Schreck, Karisa C., Kessler, Linda, Wang, Jiawan, Pratilas, Christine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122815/ https://www.ncbi.nlm.nih.gov/pubmed/35459782 http://dx.doi.org/10.1038/s41388-022-02305-x

Ejemplares similares

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Transformation by Hras(G12V) is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition
por: Chen, Xu, et al.
Publicado: (2013)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma
por: Ghilu, Samson, et al.
Publicado: (2022)

Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence
por: Li, Jenny J., et al.
Publicado: (2021)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

Clonality and Evolutionary History of Rhabdomyosarcoma
por: Chen, Li, et al.
Publicado: (2015)

Case Report: Sequential postzygotic HRAS mutation and gains of the paternal chromosome 11 carrying the mutated allele in a patient with epidermal nevus and rhabdomyosarcoma: evidence of a multiple-hit mechanism involving HRAS in oncogenic transformation
por: Zuntini, Roberta, et al.
Publicado: (2023)

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor
por: Lemberg, Kathryn M., et al.
Publicado: (2020)

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways
por: Rabik, Cara A., et al.
Publicado: (2020)

Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma
por: Dehner, Carina A., et al.
Publicado: (2021)

Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas
por: Kessler, Linda, et al.
Publicado: (2021)

Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation
por: Choo, Florence, et al.
Publicado: (2022)

Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma
por: Tenente, Inês M, et al.
Publicado: (2017)

Rhabdomyosarcoma of the head and neck: 24 cases and literature review
por: Moretti, Giovana, et al.
Publicado: (2015)

A blast from the past: ROS1 on the brain
por: Odintsov, Igor, et al.
Publicado: (2019)

Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
por: Schreck, Karisa C., et al.
Publicado: (2023)

An Essential Farnesylated Kinesin in Trypanosoma brucei
por: Engelson, Erin J., et al.
Publicado: (2011)

Mechanism of the Exchange Reaction in HRAS from Multiscale Modeling
por: Kapoor, Abhijeet, et al.
Publicado: (2014)

HRAS mutation prevalence and associated expression patterns in pheochromocytoma
por: Stenman, Adam, et al.
Publicado: (2016)

Phacomatosis pigmentokeratotica and precocious puberty associated with HRAS mutation
por: Martin, R.J., et al.
Publicado: (2017)

Towards Complete Sets of Farnesylated and Geranylgeranylated Proteins
por: Maurer-Stroh, Sebastian, et al.
Publicado: (2007)

Interacting Targets of the Farnesyl of Transducin γ-Subunit
por: Katadae, Maiko, et al.
Publicado: (2008)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

MTH1 expression is required for effective transformation by oncogenic HRAS
por: Giribaldi, Maria G., et al.
Publicado: (2015)

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
por: Wan, Xiaohua, et al.
Publicado: (2017)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG
por: Liu, Zhihui, et al.
Publicado: (2020)

Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase
por: Ohno, K, et al.
Publicado: (2011)

Farnesyl Diphosphate Synthase Inhibitors from In Silico Screening
por: Lindert, Steffen, et al.
Publicado: (2013)

Autophagic Removal of Farnesylated Carboxy-Terminal Lamin Peptides
por: Lu, Xiang, et al.
Publicado: (2018)

Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness
por: Kim, Hee Yeon, et al.
Publicado: (2018)

Protein Farnesylation Takes Part in Arabidopsis Seed Development
por: Vergès, Valentin, et al.
Publicado: (2021)

Use of Farnesyl Transferase Inhibitors in an Ageing Model in Drosophila
por: Brandt, Annely, et al.
Publicado: (2023)

Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
por: Nagase, T., et al.
Publicado: (1997)

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma
por: Miller, Michael B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mld4jfp1aoeqhtaa1e0t8096ec